Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pimavanserin open-label extension in MDD
NCT04000009Phase 3Terminated
- Sponsor
- Acadia Pharmaceuticals
- Start
- Jun 2019
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 3, open-label, single-arm trial of pimavanserin in major depressive disorder (MDD), sponsored by Acadia Pharmaceuticals. Primary endpoint: Treatment-emergent Adverse Events at 52 weeks. Started Jun 2019; status: terminated.
02
Drugs
pimavanserin
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04000009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04000009.